Johnson & Johnson delays vaccine deployment in Europe, "on hiatus" in the United States
Six women developed thromboses after receiving the Johnson & Johnson vaccine.
No formal link has yet been established.
AP - Mary Altaffer
Text by: RFI Follow
3 min
The American pharmaceutical group Johnson & Johnson said on Tuesday that it had decided to "delay the deployment" of its single-dose vaccine against Covid-19 in Europe after the decision of the American health authorities to recommend "a pause" in its use in the United States .
Publicity
Read more
US health authorities recommend "a pause" in the use of the vaccine against the Covid-19 of Johnson & Johnson, in order to investigate the appearance of serious cases of blood clots in several people in the United States.
Six women in fact developed thromboses after receiving the vaccine.
One of them died, another is hospitalized in serious condition, reports our correspondent in Washington,
Anne Corpet
.
The Federal Medicines Agency is nevertheless reassuring.
"
Nearly seven million doses of this vaccine have already been administered in the United States and this type of side effect appears extremely rare,
" said health authorities.
The FDA does not order the administration of the Johnson & Johnson vaccine to be stopped, it only recommends it.
The American pharmaceutical group argues that no formal link has yet been established between the administration of its vaccine and the appearance of these blood clots, but announces that it will delay the deployment of its product in Europe.
Johnson & Johnson "
is studying these cases with the European health authorities
," said the group in a message sent to AFP, without giving more details on the extent of the postponement of the deployment in Europe.
The European Medicines Agency (EMA) announced on Friday it was examining a possible link between Johnson & Johnson's vaccine and cases of blood clots.
His American counterpart then said he had not established a causal link at this stage between the formation of clots and the injection of the vaccine.
The White House recalls for its part that the Johnson & Johnson vaccine represents only 5% of the doses administered in the United States and estimates that the pause requested by the health authorities will not have a significant impact on the mass vaccination campaign in Classes.
However, it risks reinforcing mistrust of the coronavirus vaccine.
Newsletter
Receive all international news directly in your mailbox
I subscribe
Follow all the international news by downloading the RFI application
google-play-badge_FR
United States
Health and medicine
Coronavirus